Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Asset Writedowns and Impairment (2024)

Historic Asset Writedowns and Impairment for Seres Therapeutics (MCRB) over the last 1 years, with Q1 2024 value amounting to $3.3 million.

  • Seres Therapeutics' Asset Writedowns and Impairment changed N/A to $3.3 million in Q1 2024 from the same period last year, while for Dec 2024 it was $3.3 million, marking a year-over-year change of. This contributed to the annual value of $3.3 million for FY2024, which is N/A changed from last year.
  • As of Q1 2024, Seres Therapeutics' Asset Writedowns and Impairment stood at $3.3 million.
  • Over the past 5 years, Seres Therapeutics' Asset Writedowns and Impairment peaked at $3.3 million during Q1 2024, and registered a low of $3.3 million during Q1 2024.